Global Antibody Drug Conjugates Contract Manufacturing Market Insights, Forecast to 2028

Global Antibody Drug Conjugates Contract Manufacturing Market Insights, Forecast to 2028

Market Analysis and Insights: Global Antibody Drug Conjugates Contract Manufacturing Market

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Antibody Drug Conjugates Contract Manufacturing estimated at US$ 3,301.31 million in the year 2023, is projected to reach a revised size of US$ 9,333.76 million by 2029, growing at a CAGR of 18.91% % during the forecast period 2023-2029.

The US & Canada market for Antibody Drug Conjugates Contract Manufacturing is estimated to increase from $ 1,181.54 million in 2023 to reach $ 3,698.97 million by 2029, at a CAGR of 20.95 % during the forecast period of 2024 through 2029.

The China market for Antibody Drug Conjugates Contract Manufacturing is estimated to increase from $ 422.57 million in 2023 to reach $ 1,135.92 million by 2029, at a CAGR of 17.92% during the forecast period of 2024 through 2029.

The Europe market for Antibody Drug Conjugates Contract Manufacturing is estimated to increase from $ 924.37 million in 2023 to reach $ 2,625.59 million by 2029, at a CAGR of 19% during the forecast period of 2024 through 2029.

The global key companies of Antibody Drug Conjugates Contract Manufacturing include Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, and Curia, etc. In 2022, the global top five players had a share approximately 68.46 % in terms of revenue.

Report Includes

This report presents an overview of global market for Antibody Drug Conjugates Contract Manufacturing market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Antibody Drug Conjugates Contract Manufacturing, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody Drug Conjugates Contract Manufacturing, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody Drug Conjugates Contract Manufacturingrevenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Antibody Drug Conjugates Contract Manufacturing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Antibody Drug Conjugates Contract Manufacturing revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, and Curia, etc.

By Company

Lonza Group

Merck KGaA

Recipharm

Thermo Fisher Scientific

Abbvie

Piramal Pharma Solutions

Catalent

Sterling Pharma Solutions

Curia

Novasep

Ajinomoto Bio-Pharma Services

BSP Pharmaceuticals

Cerbios-Pharma

Goodwin Biotechnology

Segment by Type

IgG1

IgG4

Segment by Application

Solid Tumors

Hematological Malignancies

By Region

North America

United States

Canada

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Rest of Europe

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Antibody Drug Conjugates Contract Manufacturing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibody Drug Conjugates Contract Manufacturing companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug Conjugates Contract Manufacturingrevenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions